Literature DB >> 22311532

Clinical and neurocognitive profiles of subjects at high risk for psychosis with and without obsessive-compulsive symptoms.

Ji-Won Hur1, Na Young Shin, Joon Hwan Jang, Geumsook Shim, Hye Yoon Park, Jae Yeon Hwang, Sung Nyun Kim, Jung Hyun Yoo, Kyung Sue Hong, Jun Soo Kwon.   

Abstract

OBJECTIVE: Obsessive-compulsive symptoms (OCS), which are common in psychotic-spectrum illnesses, are of clinical interest because of their association with poor prognosis or cognitive dysfunction. However, few studies on the clinical and neurocognitive implications of OCS in individuals at ultra-high risk for psychosis (UHR) have been conducted.
METHOD: Sixty-five UHR subjects [24 with OCS (UHR+OCS), 41 without OCS (UHR-OCS)], and 40 healthy controls were assessed using clinical scales and neurocognitive tests.
RESULTS: Those with UHR+OCS showed more severe clinical symptoms and poorer global functioning as compared to both healthy controls and the UHR-OCS group, according to the results of the Global Assessment of Functioning, the Comprehensive Assessment of At-Risk Mental States, and the Positive and Negative Syndrome Scale (total, negative, and general scores). In the neurocognitive domain, those in the UHR-OCS group showed notably greater latency in the Stroop task and more confabulation errors in immediate recall in the Rey-Osterrieth Complex Figure Test compared with those in UHR+OCS group, whose performance levels were similar to those of the healthy control group.
CONCLUSIONS: The OCS manifested in UHR individuals was associated with a more severe clinical symptomatic presentation, including lower global functioning and more psychotic symptoms. On the other hand, those with UHR-OCS performed more poorly on some cognitive tests. The features that distinguish the groups can be used for developing prognoses and intervention strategies for the heterogeneous UHR group.

Entities:  

Mesh:

Year:  2012        PMID: 22311532     DOI: 10.1177/0004867411432851

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  7 in total

Review 1.  Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.

Authors:  Randal G Ross; Robert Freedman
Journal:  Schizophr Bull       Date:  2015-05-04       Impact factor: 9.306

2.  Identifying Schizo-Obsessive Comorbidity by Tract-Based Spatial Statistics and Probabilistic Tractography.

Authors:  Yong-Ming Wang; Zhuo-Ya Yang; Xin-Lu Cai; Han-Yu Zhou; Rui-Ting Zhang; Han-Xue Yang; Yun-Si Liang; Xiong-Zhao Zhu; Kristoffer Hougaard Madsen; Thomas Alrik Sørensen; Arne Møller; Zhen Wang; Eric F C Cheung; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2020-02-26       Impact factor: 9.306

Review 3.  Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature.

Authors:  Chloé Tezenas du Montcel; Antoine Pelissolo; Franck Schürhoff; Baptiste Pignon
Journal:  Curr Psychiatry Rep       Date:  2019-07-01       Impact factor: 5.285

4.  Altered Thalamo-Cortical White Matter Connectivity: Probabilistic Tractography Study in Clinical-High Risk for Psychosis and First-Episode Psychosis.

Authors:  Kang Ik K Cho; Martha E Shenton; Marek Kubicki; Wi Hoon Jung; Tae Young Lee; Je-Yeon Yun; Sung Nyun Kim; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2015-11-23       Impact factor: 9.306

5.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

6.  Meta-analysis of cognitive functioning in patients with psychotic disorders and obsessive-compulsive symptoms.

Authors:  Lieuwe de Haan; Frederike Schirmbeck; Lotte Dijkstra; Jentien Vermeulen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-08-11       Impact factor: 5.270

Review 7.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.